Patel, R. R., Jiang, C. Y., Thomas, Z., Jindal, T., Jang, A., Zhong, J. Y., Bakaloudi, D., Oh, E., Nguyen, C. B., Casas, S. J., Tripathi, A., Grivas, P., Tsung, I., Campbell, M. T., Alhalabi, O., Khaki, A. R., Chen, Z., Fu, P., Koshkin, V. S., Brown, J. R. (2026). Risk and patterns of recurrence for patients (pts) with advanced urothelial carcinoma (aUC) metastatic to liver after response to enfortumab vedotin + pembrolizumab (EVP).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4584